
  
    
      
        Background_NNP
        In_IN terms_NNS of_IN avoiding_VBG bias_NN ,_, the_DT most_RBS rigorous_JJ method_NN for_IN
        evaluating_VBG a_DT medical_JJ intervention_NN is_VBZ the_DT randomized_JJ
        controlled_VBN trial_NN ._. However_RB ,_, many_JJ clinical_JJ investigators_NNS are_VBP
        unable_JJ to_TO conduct_VB a_DT randomized_JJ trial_NN because_IN of_IN excessive_JJ
        cost_NN or_CC required_VBN effort_NN or_CC difficulty_NN overcoming_VBG strongly_RB
        held_VBN beliefs_NNS among_IN health_NN care_NN providers_NNS or_CC patients_NNS ._. In_IN
        these_DT situations_NNS ,_, a_DT clinical_JJ investigator_NN may_MD consider_VB a_DT
        design_NN and_CC analysis_NN based_VBN on_IN observational_NN data_NNS (_( Table_NNP
        1_LS )_) ._.
        One_CD common_JJ method_NN of_IN inference_NN from_IN observational_NN data_NNS
        is_VBZ the_DT cohort_NN study_NN with_IN an_DT adjustment_NN for_IN risk_NN factors_NNS
        using_VBG ,_, for_IN example_NN ,_, regression_NN models_NNS [_NN 1_CD ]_NN and_CC propensity_NN
        scores_NNS [_NN 2_CD ]_NN ._. In_IN some_DT situations_NNS ,_, estimates_NNS from_IN
        high-quality_JJ cohort_NN studies_NNS have_VBP been_VBN similar_JJ to_TO those_DT from_IN
        randomized_JJ trials_NNS [_NN 2_CD ]_NN [_NN 3_CD ]_NN [_NN 4_CD ]_NN [_NN 5_CD ]_NN ._. However_RB there_EX
        are_VBP some_DT notable_JJ exceptions_NNS ,_, including_VBG studies_NNS of_IN the_DT
        effect_NN of_IN beta-carotene_JJ on_IN cardiovascular_JJ mortality_NN [_NN 6_CD ]_NN [_NN
        7_CD ]_NN ,_, the_DT effect_NN of_IN hormone_NN therapy_NN on_IN the_DT rate_NN of_IN
        cardiovascular_JJ disease_NN [_NN 8_CD ]_NN ,_, the_DT effect_NN of_IN epidural_NN
        analgesia_NN on_IN the_DT probability_NN of_IN Cesarean_NNP section_NN [_NN 9_CD ]_NN ,_,
        the_DT effect_NN of_IN beta-blockers_JJ on_IN mortality_NN [_NN 10_CD ]_NN ,_, and_CC the_DT
        effect_NN of_IN aspirin_NN on_IN the_DT risk_NN of_IN colorectal_NN cancer_NN [_NN 11_CD ]_NN ._.
        Some_DT of_IN the_DT discrepancy_NN between_IN the_DT results_NNS of_IN these_DT high_JJ
        quality_NN cohort_NN studies_NNS and_CC randomized_JJ trials_NNS may_MD be_VB
        explained_VBN by_IN differences_NNS in_IN the_DT intervention_NN ,_, patient_NN
        population_NN ,_, or_CC duration_NN of_IN follow-up_JJ ._. Nevertheless_RB ,_, a_DT major_JJ
        reason_NN for_IN bias_NN with_IN cohort_NN studies_NNS is_VBZ the_DT failure_NN to_TO
        adjust_VB for_IN 
        all_DT factors_NNS related_VBD the_DT receipt_NN of_IN
        intervention_NN and_CC outcome_NN ._. This_DT failure_NN may_MD be_VB due_JJ to_TO the_DT
        inability_NN to_TO identify_VB or_CC collect_VB the_DT necessary_JJ data_NN ,_, or_CC the_DT
        difficulty_NN measuring_VBG or_CC quantifying_VBG subjective_JJ factors_NNS such_JJ
        as_IN clinical_JJ judgment_NN ._. For_IN a_DT fuller_JJR discussion_NN of_IN how_WRB an_DT
        omitted_VBN factor_NN related_VBN to_TO receipt_NN of_IN intervention_NN and_CC
        outcome_NN can_MD bias_NN results_NNS in_IN a_DT cohort_NN study_NN but_CC not_RB a_DT
        randomized_JJ trial_NN see_VB Baker_NNP and_CC Kramer_NNP [_NN 12_CD ]_NN ._.
      
      
        Methods_NNP
        An_DT alternative_NN and_CC less_RBR widely_RB known_VBN approach_NN is_VBZ the_DT
        paired_VBN availability_NN design_NN for_IN historical_JJ controls_NNS [_NN 9_CD ]_NN [_NN
        13_CD ]_NN [_NN 14_CD ]_NN ._. As_IN we_PRP describe_VBP in_IN more_JJR detail_NN ,_, the_DT paired_VBN
        availability_NN design_NN consists_VBZ of_IN comparing_VBG outcomes_NNS in_IN
        multiple_JJ hospitals_NNS or_CC medical_JJ centers_NNS before_IN versus_CC after_IN a_DT
        change_NN in_IN availability_NN of_IN a_DT medical_JJ intervention_NN ._. To_TO adjust_VB
        for_IN different_JJ changes_NNS in_IN availability_NN among_IN the_DT hospitals_NNS
        or_CC medical_JJ centers_NNS ,_, the_DT test_NN statistic_NN for_IN each_DT hospital_NN or_CC
        medical_JJ center_NN is_VBZ the_DT difference_NN in_IN outcome_NN before_IN and_CC
        after_IN the_DT change_NN in_IN availability_NN divided_VBN by_IN the_DT change_NN in_IN
        the_DT fraction_NN of_IN patients_NNS who_WP receive_VBP the_DT intervention_NN ._.
        These_DT test_NN statistics_NNS are_VBP combined_VBN in_IN a_DT meta-analysis_JJ ,_,
        which_WDT weights_NNS the_DT statistic_NN from_IN each_DT hospital_NN according_VBG to_TO
        the_DT reciprocal_JJ of_IN the_DT variance_NN ,_, a_DT quantity_NN that_WDT depends_VBZ on_IN
        sample_NN size_NN and_CC the_DT change_NN in_IN availability_NN ._.
        The_DT paired_VBN availability_NN design_NN avoids_VBZ many_JJ of_IN the_DT biases_NNS
        of_IN analyses_NNS based_VBN on_IN traditional_JJ historical_JJ controls_NNS ._. With_IN
        traditional_JJ historical_JJ controls_NNS ,_, investigators_NNS compare_VBP
        outcome_NN among_IN subjects_NNS who_WP receive_VBP a_DT new_JJ intervention_NN with_IN
        outcome_NN among_IN a_DT previous_JJ group_NN of_IN subjects_NNS who_WP received_VBD the_DT
        standard_JJ intervention_NN ._. Selection_NN bias_NN often_RB arises_VBZ because_IN
        subjects_NNS who_WP receive_VBP the_DT new_JJ intervention_NN are_VBP typically_RB not_RB
        comparable_JJ to_TO subjects_NNS who_WP received_VBD the_DT standard_JJ
        intervention_NN [_NN 15_CD ]_NN ._. The_DT paired_VBN availability_NN design_NN
        reduces_VBZ selection_NN bias_NN because_IN the_DT comparison_NN is_VBZ between_IN 
        all_DT subjects_NNS (_( those_DT who_WP received_VBD the_DT
        intervention_NN and_CC those_DT who_WP did_VBD not_RB )_) before_IN the_DT change_NN in_IN
        availability_NN and_CC 
        all_DT subjects_NNS (_( those_DT who_WP received_VBD the_DT
        intervention_NN and_CC those_DT who_WP did_VBD not_RB )_) after_IN the_DT change_NN in_IN
        availability_NN ._. Thus_RB the_DT intervention_NN is_VBZ the_DT availability_NN of_IN
        treatment_NN ,_, instead_RB of_IN the_DT receipt_NN of_IN treatment_NN ._. If_IN the_DT
        sample_NN of_IN all_DT subjects_NNS eligible_JJ for_IN intervention_NN is_VBZ
        comparable_JJ before_IN and_CC after_IN the_DT change_NN in_IN availability_NN ,_, one_PRP
        can_MD obtain_VB an_DT unbiased_JJ estimate_NN of_IN the_DT effect_NN of_IN a_DT change_NN
        in_IN availability_NN by_IN comparing_VBG outcome_NN among_IN all_DT subjects_NNS
        before_IN the_DT change_NN in_IN availability_NN with_IN the_DT outcome_NN among_IN
        all_DT subjects_NNS after_IN the_DT change_NN in_IN availability_NN ._. This_DT is_VBZ
        analogous_JJ to_TO obtaining_VBG an_DT unbiased_JJ estimate_NN of_IN the_DT effect_NN
        of_IN intent-to-treat_JJ by_IN comparing_VBG outcomes_NNS among_IN all_DT subjects_NNS
        in_IN each_DT arm_NN of_IN a_DT randomized_JJ trial_NN subject_JJ to_TO
        noncompliance_NN ._.
        For_IN both_DT the_DT paired_VBN availability_NN design_NN and_CC randomized_JJ
        trials_NNS subject_JJ to_TO noncompliance_NN ,_, the_DT ideal_JJ goal_NN is_VBZ an_DT
        unbiased_JJ estimate_NN of_IN the_DT effect_NN of_IN receipt_NN of_IN treatment_NN ._. If_IN
        certain_JJ requirements_NNS hold_VBP ,_, which_WDT we_PRP discuss_VBP ,_, a_DT simple_JJ
        adjustment_NN gives_VBZ an_DT unbiased_JJ estimate_NN of_IN the_DT effect_NN of_IN
        receipt_NN of_IN treatment_NN in_IN the_DT paired_VBN availability_NN design_NN ._.
        Similarly_RB ,_, in_IN certain_JJ situations_NNS involving_VBG randomized_JJ
        trials_NNS with_IN noncompliance_NN ,_, such_JJ as_IN switching_VBG interventions_NNS
        immediately_RB after_IN randomization_NN ,_, a_DT similar_JJ adjustment_NN also_RB
        yields_VBZ an_DT unbiased_JJ estimate_NN of_IN the_DT effect_NN of_IN receipt_NN of_IN
        treatment_NN [_NN 16_CD ]_NN [_NN 17_CD ]_NN ._. Readers_NNS interested_VBN in_IN a_DT formal_JJ
        mathematical_JJ statement_NN of_IN these_DT requirements_NNS and_CC how_WRB they_PRP
        give_VBP rise_NN to_TO the_DT simple_JJ estimate_NN should_MD consult_VB references_NNS
        [_NN 9_CD ]_NN [_NN 13_CD ]_NN [_NN 14_CD ]_NN [_NN 16_CD ]_NN [_NN 17_CD ]_NN ._.
      
      
        Results_NNS
        
          Design_NNP
          The_DT paired_VBN availability_NN design_NN uses_VBZ data_NNS collected_VBN in_IN
          either_DT a_DT prospective_JJ or_CC retrospective_NN manner_NN ,_, or_CC a_DT
          combination_NN of_IN the_DT two_CD ._. Although_IN implementing_VBG a_DT
          multi-center_JJ study_NN may_MD initially_RB appear_VB burdensome_JJ ,_, two_CD
          mitigating_JJ factors_NNS lessen_VB the_DT burden_NN :_: (_( 1_LS )_) randomization_NN
          is_VBZ not_RB required_VBN and_CC (_( 2_LS )_) investigators_NNS need_MD not_RB collect_VB
          data_NNS on_IN risk_NN factors_NNS if_IN the_DT requirements_NNS hold_VBP ._. The_DT
          requirements_NNS (_( to_TO follow_VB )_) are_VBP most_RBS likely_JJ to_TO hold_VB when_WRB the_DT
          time_NN period_NN for_IN the_DT entire_JJ study_NN is_VBZ not_RB too_RB long_JJ ._. We_PRP
          recommend_VBP limiting_VBG the_DT total_JJ study_NN duration_NN to_TO not_RB more_JJR
          than_IN two_CD years_NNS ,_, recognizing_VBG there_EX may_MD be_VB exceptions_NNS due_JJ
          to_TO patient_NN accrual_NN rate_NN ,_, intervention_NN ,_, and_CC outcome_NN ._. If_IN
          availability_NN changes_NNS gradually_RB ,_, it_PRP is_VBZ often_RB sufficient_JJ to_TO
          split_VB the_DT data_NNS halfway_RB between_IN the_DT start_NN of_IN the_DT "_'' before_IN "_''
          period_NN and_CC the_DT end_NN of_IN the_DT "_'' after_IN "_'' period_NN ;_: although_IN more_RBR
          sophisticated_JJ statistical_JJ techniques_NNS can_MD be_VB employed_VBN [_NN 9_CD
          ]_NN
          The_DT change_NN in_IN availability_NN between_IN the_DT "_'' before_IN "_'' and_CC
          "_'' after_IN "_'' periods_NNS can_MD take_VB different_JJ forms_NNS which_WDT do_VBP not_RB
          affect_VB the_DT design_NN or_CC analysis_NN ._. With_IN fixed_VBN availability_NN ,_,
          the_DT intervention_NN is_VBZ available_JJ to_TO all_DT subjects_NNS who_WP arrive_VBP
          during_IN a_DT certain_JJ time_NN of_IN day_NN or_CC day_NN of_IN the_DT week_NN ._. With_IN
          random_JJ availability_NN ,_, the_DT intervention_NN is_VBZ available_JJ only_RB
          if_IN the_DT necessary_JJ personnel_NNS or_CC equipment_NN is_VBZ available_JJ ,_,
          which_WDT occurs_VBZ at_IN random_JJ ._. In_IN either_DT case_NN ,_, subjects_NNS can_MD
          decide_VB whether_IN or_CC not_RB to_TO undergo_VB the_DT intervention_NN ._.
          The_DT study_NN design_NN has_VBZ five_CD requirements_NNS for_IN making_VBG
          appropriate_JJ inference_NN :_: stable_JJ population_NN ,_, stable_JJ
          treatment_NN ,_, stable_JJ evaluation_NN ,_, stable_JJ preference_NN ,_, and_CC no_DT
          effect_NN of_IN availability_NN on_IN the_DT effect_NN of_IN intervention_NN
          (_( Table_NNP 2_LS )_) ._. Stable_NNP population_NN ,_, treatment_NN ,_, and_CC evaluation_NN ,_,
          are_VBP required_VBN for_IN appropriate_JJ inference_NN in_IN any_DT medical_JJ
          study_NN involving_VBG comparisons_NNS over_IN time_NN ._. Stable_NNP preference_NN
          and_CC no_DT effect_NN of_IN availability_NN on_IN the_DT effect_NN of_IN
          intervention_NN ,_, are_VBP needed_VBN to_TO adjust_VB for_IN differences_NNS in_IN
          availability_NN among_IN hospitals_NNS or_CC medical_JJ centers_NNS ._.
          The_DT first_JJ requirement_NN ,_, stable_JJ population_NN ,_, is_VBZ that_IN the_DT
          composition_NN of_IN subjects_NNS eligible_JJ for_IN the_DT intervention_NN
          should_MD not_RB change_VB from_IN the_DT "_'' before_IN "_'' to_TO the_DT "_'' after_IN "_'' period_NN
          in_IN ways_NNS that_WDT would_MD affect_VB outcome_NN ._. This_DT requirement_NN would_MD
          be_VB violated_VBN if_IN subjects_NNS seek_VBP treatment_NN because_IN of_IN the_DT
          availability_NN of_IN the_DT treatment_NN under_IN study_NN ._. The_DT assumption_NN
          is_VBZ therefore_RB violated_VBN if_IN hospitals_NNS advertise_VBP the_DT
          availability_NN of_IN a_DT new_JJ diagnostic_JJ test_NN or_CC medical_JJ
          intervention_NN ._. In_IN addition_NN ,_, each_DT hospital_NN or_CC medical_JJ
          center_NN should_MD serve_VB a_DT well-defined_JJ population_NN with_IN little_JJ
          in-_NN or_CC out-_NN migration_NN ._. Examples_NNS include_VBP the_DT only_JJ hospital_NN
          in_IN a_DT geographic_JJ region_NN or_CC a_DT military_JJ medical_JJ center_NN ._. The_DT
          presence_NN of_IN two_CD or_CC more_JJR hospitals_NNS in_IN a_DT region_NN could_MD
          introduce_VB bias_NN if_IN the_DT new_JJ intervention_NN were_VBD available_JJ in_IN
          only_RB one_CD hospital_NN and_CC it_PRP were_VBD not_RB possible_JJ to_TO exclude_VB
          from_IN the_DT analysis_NN patients_NNS who_WP switched_VBD hospitals_NNS to_TO
          undergo_VB the_DT new_JJ intervention_NN ._. The_DT stable_JJ population_NN
          requirement_NN would_MD also_RB be_VB violated_VBN by_IN changes_NNS in_IN
          eligibility_NN criteria_NNS over_IN time_NN ._. If_IN eligibility_NN is_VBZ
          determined_VBN by_IN a_DT medical_JJ diagnosis_NN ,_, the_DT method_NN of_IN
          diagnosis_NN must_MD not_RB change_VB over_IN time_NN ._. Lastly_NNP the_DT stable_JJ
          population_NN requirement_NN would_MD be_VB violated_VBN if_IN the_DT
          underlying_VBG prognosis_NN of_IN patients_NNS changed_VBN over_IN time_NN ._. For_IN
          example_NN in_IN a_DT study_NN of_IN treatment_NN for_IN a_DT viral_JJ infection_NN
          which_WDT is_VBZ spreading_VBG through_IN a_DT population_NN ,_, the_DT most_RBS
          susceptible_JJ subjects_NNS would_MD likely_RB enter_VB the_DT trial_NN first_NN ,_,
          which_WDT would_MD violate_VB the_DT stable_JJ population_NN requirement_NN if_IN
          they_PRP have_VBP the_DT worse_JJR prognosis_NN after_IN infection_NN ._.
          The_DT second_JJ requirement_NN ,_, stable_JJ treatment_NN ,_, is_VBZ that_IN the_DT
          patient_NN management_NN unrelated_JJ to_TO the_DT intervention_NN is_VBZ
          identical_JJ in_IN the_DT "_'' before_IN "_'' and_CC "_'' after_IN "_'' groups_NNS ._. Thus_RB ,_, in_IN
          studying_VBG the_DT effect_NN of_IN epidural_NN analgesia_NN on_IN the_DT
          probability_NN of_IN Caesarian_NNP section_NN ,_, other_JJ forms_NNS of_IN
          obstetric_JJ management_NN should_MD be_VB constant_JJ over_IN time_NN ._.
          Similarly_RB ,_, in_IN studying_VBG the_DT effect_NN of_IN an_DT intense_JJ
          chemotherapeutic_JJ regimen_NN for_IN cancer_NN on_IN survival_NN ,_, the_DT type_NN
          of_IN antibiotic_JJ should_MD not_RB change_VB of_IN over_IN time_NN ,_, as_IN new_JJ and_CC
          more_RBR effective_JJ antibiotics_NNS could_MD lower_JJR treatment-related_JJ
          mortality_NN irrespective_RB of_IN the_DT efficacy_NN of_IN the_DT anticancer_NN
          regimen_NN ._.
          The_DT third_JJ requirement_NN ,_, stable_JJ evaluation_NN ,_, is_VBZ that_IN the_DT
          method_NN of_IN evaluation_NN is_VBZ identical_JJ in_IN the_DT "_'' before_IN "_'' and_CC
          "_'' after_IN "_'' groups_NNS ._. For_IN example_NN ,_, the_DT use_NN of_IN a_DT new_JJ radiologic_JJ
          test_NN to_TO stage_VB cancer_NN in_IN the_DT "_'' after_IN "_'' group_NN may_MD
          artifactually_RB improve_VB prognosis_NN of_IN each_DT stage_NN ,_,
          independent_JJ of_IN the_DT therapy_NN [_NN 18_CD ]_NN ._.
          Because_IN the_DT paired_VBN availability_NN design_NN involves_VBZ
          multiple_JJ hospitals_NNS or_CC medical_JJ centers_NNS ,_, random_JJ violations_NNS
          of_IN the_DT stable_JJ population_NN ,_, treatment_NN ,_, and_CC evaluation_NN
          requirements_NNS will_MD tend_VB to_TO average_VB out_IN ,_, and_CC not_RB affect_VB the_DT
          conclusion_NN ._. The_DT main_JJ concern_NN is_VBZ with_IN systematic_JJ
          violations_NNS ._. To_TO minimize_VB systematic_JJ violations_NNS ,_, if_IN
          possible_JJ ,_, a_DT wide_JJ variety_NN of_IN hospitals_NNS or_CC medical_JJ centers_NNS
          should_MD be_VB studied_VBN ._.
          The_DT fourth_JJ requirement_NN ,_, stable_JJ preference_NN ,_, is_VBZ
          strengthened_VBN in_IN the_DT absence_NN of_IN new_JJ information_NN in_IN the_DT
          "_'' after_IN "_'' period_NN that_WDT would_MD change_VB a_DT subject_NN 's_POS preference_NN
          for_IN the_DT medical_JJ intervention_NN ._. This_DT requirement_NN could_MD be_VB
          violated_VBN by_IN a_DT widely_RB publicized_VBN report_NN of_IN a_DT harmful_JJ side_NN
          effect_NN of_IN the_DT new_JJ treatment_NN ,_, or_CC direct-to-consumer_JJ
          advertising_NN of_IN the_DT intervention_NN to_TO consumers_NNS ._. To_TO the_DT best_JJS
          of_IN our_PRP$ knowledge_NN ,_, in_IN the_DT paired_VBN availability_NN design_NN to_TO
          study_VB the_DT effect_NN of_IN epidural_NN analgesia_NN on_IN the_DT probability_NN
          of_IN Cesarean_NNP section_NN ,_, there_EX were_VBD no_DT credible_JJ reports_NNS of_IN
          either_DT detrimental_JJ or_CC beneficial_JJ side_NN effects_NNS to_TO the_DT
          mother_NN or_CC fetus_NN from_IN epidural_NN analgesia_NN and_CC no_DT relevant_JJ
          direct-to-consumer_JJ advertising_NN ._. In_IN contrast_NN ,_, if_IN the_DT media_NNS
          reported_VBD preliminary_JJ results_NNS that_IN radioactive_JJ seed_NN
          implants_NNS had_VBD fewer_JJR side_NN effects_NNS than_IN previous_JJ approaches_NNS
          for_IN treating_VBG prostate_NN cancer_NN ,_, healthier_JJR subjects_NNS who_WP care_VBP
          most_JJS about_IN the_DT side_NN effects_NNS may_MD be_VB more_RBR likely_JJ to_TO request_VB
          the_DT new_JJ therapy_NN than_IN less_JJR healthy_JJ subjects_NNS who_WP only_RB care_NN
          if_IN treatment_NN reduces_VBZ the_DT risk_NN of_IN mortality_NN ._.
          The_DT fifth_JJ requirement_NN is_VBZ that_IN the_DT effect_NN of_IN the_DT
          intervention_NN on_IN outcome_NN does_VBZ not_RB change_VB with_IN a_DT change_NN in_IN
          availability_NN ._. Importantly_NNP ,_, it_PRP applies_VBZ only_RB when_WRB there_EX are_VBP
          some_DT subjects_NNS in_IN the_DT "_'' before_IN "_'' group_NN who_WP undergo_VBP the_DT
          intervention_NN ._. Mathematically_NNP the_DT following_VBG two_CD
          assumptions_NNS are_VBP required_VBN to_TO estimate_VB method_NN effectiveness_NN
          [_NN 9_CD ]_NN [_NN 13_CD ]_NN [_NN 14_CD ]_NN ._. (_( 1_LS )_) Subjects_NNP in_IN the_DT "_'' before_IN "_'' group_NN
          who_WP undergo_VBP intervention_NN have_VBP comparable_JJ counterparts_NNS in_IN
          the_DT "_'' after_IN "_'' group_NN who_WP undergo_VBP intervention_NN (_( which_WDT is_VBZ
          justified_JJ by_IN the_DT other_JJ requirements_NNS )_) 
          and_CC the_DT effect_NN of_IN intervention_NN is_VBZ
          the_DT same_JJ in_IN both_DT groups_NNS ,_, i_NNP ._. e_SYM ._. it_PRP does_VBZ not_RB depend_VB on_IN a_DT
          change_NN in_IN availability_NN ._. (_( 2_LS )_) Subjects_NNP in_IN the_DT "_'' after_IN "_'' group_NN
          who_WP do_VBP 
          not_RB undergo_VB the_DT intervention_NN have_VBP
          comparable_JJ counterparts_NNS in_IN the_DT "_'' before_IN "_'' group_NN who_WP do_VBP 
          not_RB undergo_VB the_DT intervention_NN (_( as_IN
          justified_JJ by_IN the_DT other_JJ requirements_NNS )_) 
          and_CC the_DT effect_NN of_IN no_DT intervention_NN
          is_VBZ the_DT same_JJ in_IN both_DT groups_NNS ._. By_IN definition_NN no_DT intervention_NN
          is_VBZ the_DT same_JJ in_IN the_DT "_'' before_IN "_'' and_CC "_'' after_IN "_'' groups_NNS ,_, so_IN a_DT
          change_NN in_IN availability_NN of_IN intervention_NN would_MD have_VB no_DT
          bearing_NN on_IN (_( 2_LS )_) ._. Thus_RB the_DT effect_NN of_IN a_DT change_NN in_IN
          availability_NN on_IN the_DT effect_NN of_IN the_DT intervention_NN only_RB
          pertains_VBZ to_TO (_( 1_LS )_) ,_, where_WRB subjects_NNS in_IN the_DT "_'' before_IN "_'' group_NN
          undergo_VBP intervention_NN ._.
          The_DT fifth_JJ requirement_NN would_MD be_VB violated_VBN if_IN increased_VBN
          availability_NN caused_VBD some_DT subjects_NNS to_TO undergo_VB the_DT
          intervention_NN sooner_RBR in_IN the_DT course_NN of_IN the_DT disease_NN ,_,
          changing_VBG prognosis_NN ._. The_DT fifth_JJ requirement_NN would_MD also_RB be_VB
          violated_VBN if_IN there_EX were_VBD a_DT learning_VBG curve_NN with_IN new_JJ
          intervention_NN ,_, such_JJ as_IN a_DT surgical_JJ technique_NN that_WDT improves_VBZ
          with_IN the_DT number_NN of_IN procedures_NNS ._. If_IN such_JJ violations_NNS are_VBP
          likely_JJ ,_, the_DT design_NN should_MD be_VB restricted_VBN to_TO hospitals_NNS or_CC
          medical_JJ centers_NNS where_WRB no_DT subjects_NNS in_IN the_DT "_'' before_IN "_'' group_NN
          received_VBD the_DT intervention_NN ._.
          Baker_NNP and_CC Lindeman_NNP provided_VBD a_DT formula_NN to_TO calculate_VB the_DT
          required_JJ the_DT number_NN of_IN hospitals_NNS or_CC medical_JJ centers_NNS to_TO
          achieve_VB sufficient_JJ power_NN for_IN hypothesis_NNS testing_NN [_NN 13_CD ]_NN ._.
          However_RB ,_, the_DT formula_NN may_MD be_VB difficult_JJ to_TO use_VB if_IN the_DT
          required_JJ information_NN on_IN the_DT likely_JJ variability_NN of_IN an_DT
          effect_NN over_IN hospitals_NNS or_CC medical_JJ centers_NNS is_VBZ not_RB readily_RB
          available_JJ ._. In_IN such_JJ situations_NNS ,_, as_IN a_DT rule_NN of_IN thumb_NN ,_, we_PRP
          recommend_VBP a_DT minimum_NN of_IN 10_CD hospitals_NNS or_CC medical_JJ centers_NNS ,_,
          with_IN 15_CD preferable_JJ ,_, and_CC 20_CD ideal_JJ ._.
        
        
          Analysis_NNP
          The_DT purpose_NN of_IN the_DT analysis_NN is_VBZ to_TO estimate_VB the_DT effect_NN
          of_IN the_DT receipt_NN of_IN the_DT medical_JJ intervention_NN ,_, which_WDT is_VBZ also_RB
          called_VBN method-effectiveness_JJ [_NN 16_CD ]_NN ._. As_IN derived_VBN by_IN Baker_NNP
          and_CC Lindeman_NNP [_NN 9_CD ]_NN [_NN 13_CD ]_NN ,_, if_IN the_DT aforementioned_JJ
          requirements_NNS hold_VBP ,_, for_IN each_DT hospital_NN or_CC medical_JJ center_NN ,_,
          the_DT estimated_VBN effect_NN of_IN receipt_NN of_IN treatment_NN is_VBZ
          D_NNP /_NN F_NN ,_, where_WRB
          D_NNP =_SYM difference_NN in_IN outcome_NN before_IN and_CC after_IN change_NN in_IN
          availability_NN
          F_NN =_SYM fraction_NN that_WDT received_JJ intervention_NN 
          after_IN change_NN in_IN availability_NN -_:
          fraction_NN that_WDT received_JJ intervention_NN 
          before_IN change_NN in_IN availability_NN
          If_IN the_DT outcome_NN measure_NN is_VBZ a_DT continuous_JJ variable_JJ such_JJ
          as_IN blood_NN measure_NN ,_, D_NNP is_VBZ a_DT difference_NN in_IN the_DT average_JJ
          outcomes_NNS between_IN the_DT "_'' before_IN "_'' and_CC "_'' after_IN "_'' groups_NNS ._. If_IN the_DT
          outcome_NN measure_NN is_VBZ binary_JJ ,_, such_JJ as_IN success_NN or_CC failure_NN ,_, D_NNP
          is_VBZ a_DT difference_NN in_IN the_DT fraction_NN who_WP fail_VBP or_CC succeed_VB in_IN
          the_DT "_'' before_IN "_'' and_CC "_'' after_IN "_'' groups_NNS ._.
          The_DT above_JJ estimate_NN ,_, D_NNP /_NN F_NN ,_, has_VBZ an_DT analog_NN in_IN the_DT analysis_NN
          of_IN randomized_JJ trials_NNS when_WRB some_DT subjects_NNS switch_VBP treatments_NNS
          soon_RB after_IN randomization_NN ._. With_IN an_DT intent-to-treat_JJ
          analysis_NN ,_, one_PRP can_MD estimate_VB use-effectiveness_JJ ,_, D_NNP *_NN ,_, which_WDT
          is_VBZ the_DT effect_NN of_IN random_JJ assignment_NN of_IN treatment_NN on_IN
          outcome_NN ._. Similarly_RB ,_, one_PRP can_MD estimate_VB F_NN *_NN ,_, the_DT fraction_NN of_IN
          subjects_NNS in_IN the_DT study_NN group_NN that_WDT received_VBD the_DT new_JJ
          treatment_NN minus_CC the_DT fraction_NN of_IN subjects_NNS in_IN the_DT control_NN
          group_NN that_WDT received_VBD the_DT new_JJ treatment_NN ._. Invoking_NNP an_DT
          assumption_NN analogous_JJ to_TO the_DT fifth_JJ requirement_NN for_IN the_DT
          paired_VBN availability_NN design_NN ,_, the_DT estimated_VBN
          method-effectiveness_JJ is_VBZ D_NNP *_NN /_NN F_NN *_NN [_NN 17_CD ]_NN ._.
          As_IN illustrated_VBN in_IN the_DT calculations_NNS accompanying_VBG Table_NNP
          3_CD ,_, we_PRP use_VBP a_DT standard_JJ approach_NN for_IN a_DT random_JJ effects_NNS
          meta-analysis_JJ [_NN 19_CD ]_NN to_TO summarize_VB the_DT estimated_VBN effect_NN of_IN
          receipt_NN of_IN treatment_NN over_IN all_DT studies_NNS ._. The_DT summary_NN
          statistic_NN is_VBZ a_DT weighted_JJ average_NN of_IN the_DT estimated_VBN effect_NN
          of_IN receipt_NN of_IN treatment_NN for_IN each_DT hospital_NN or_CC medical_JJ
          center_NN ,_, where_WRB the_DT weight_NN for_IN each_DT hospital_NN or_CC medical_JJ
          center_NN is_VBZ the_DT reciprocal_JJ of_IN the_DT sum_NN of_IN the_DT sampling_VBG
          variance_NN and_CC the_DT variance_NN of_IN the_DT true_JJ effect_NN over_IN the_DT
          studies_NNS ._. The_DT sampling_VBG variance_NN of_IN the_DT estimated_VBN effect_NN of_IN
          receipt_NN of_IN treatment_NN ,_, the_DT variability_NN due_JJ to_TO taking_VBG a_DT
          sample_NN from_IN a_DT hypothetical_JJ larger_JJR population_NN ,_,
          approximately_RB equals_VBZ the_DT sampling_VBG variance_NN of_IN the_DT
          numerator_NN ,_, which_WDT is_VBZ a_DT standard_JJ calculation_NN ,_, divided_VBN by_IN
          denominator_NN squared_VBN ._. The_DT variability_NN of_IN the_DT true_JJ effect_NN ,_,
          which_WDT arises_VBZ because_IN the_DT medical_JJ intervention_NN is_VBZ not_RB
          exactly_RB identical_JJ among_IN all_DT hospitals_NNS ,_, is_VBZ computed_JJ using_VBG
          the_DT formula_NN in_IN DerSimonian_NNP and_CC Laird_NNP [_NN 19_CD ]_NN ._. The_DT
          standard_JJ error_NN of_IN the_DT summary_NN statistic_NN is_VBZ the_DT square_JJ
          root_NN of_IN the_DT reciprocal_JJ of_IN the_DT sum_NN of_IN the_DT weights_NNS ._. An_DT
          approximate_JJ 95_CD %_NN confidence_NN interval_NN is_VBZ computed_JJ as_IN the_DT
          summary_NN statistic_NN plus_CC or_CC minus_CC the_DT standard_JJ error_NN
          multiplied_VBN by_IN the_DT 97_CD 1_CD /_NN 2_CD percentile_NN of_IN a_DT t-distribution_JJ
          with_IN degrees_NNS of_IN freedom_NN equal_JJ to_TO the_DT number_NN of_IN hospitals_NNS
          or_CC medical_JJ centers_NNS minus_CC one_CD [_NN 20_CD ]_NN ._. This_DT value_NN can_MD be_VB
          found_VBN in_IN tables_NNS in_IN many_JJ statistics_NNS books_NNS ;_: for_IN example_NN for_IN
          11_CD hospitals_NNS ,_, there_EX are_VBP 10_CD degrees_NNS of_IN freedom_NN and_CC the_DT
          value_NN is_VBZ 2_CD ._. 23_CD ._.
        
        
          Example_NN
          Baker_NNP and_CC Lindeman_NNP applied_VBD the_DT paired_VBN availability_NN
          design_NN to_TO study_VB the_DT effect_NN of_IN epidural_NN analgesia_NN on_IN the_DT
          probability_NN of_IN Cesarean_NNP section_NN [_NN 9_CD ]_NN ._. They_PRP identified_VBD
          11_CD hospitals_NNS or_CC medical_JJ centers_NNS where_WRB epidural_NN analgesia_NN
          was_VBD introduced_VBN ,_, expanded_VBN ,_, or_CC discontinued_VBN ._. Stable_NNP
          population_NN and_CC stable_JJ treatment_NN requirements_NNS were_VBD
          supported_VBN by_IN the_DT reports_NNS of_IN the_DT investigators_NNS ._. Stable_NNP
          evaluation_NN held_VBN because_IN of_IN the_DT unambiguous_JJ nature_NN of_IN the_DT
          outcome_NN ._. The_DT stable_JJ preference_NN requirement_NN likely_RB held_VBN ,_,
          as_IN there_EX were_VBD no_DT widely_RB published_VBN reports_NNS concerning_VBG
          risks_NNS or_CC benefits_NNS of_IN epidural_NN analgesia_NN and_CC no_DT
          direct-to-consumer_JJ advertising_NN of_IN the_DT procedure_NN ._. Because_IN
          increased_VBN availability_NN would_MD likely_RB cause_VB some_DT subjects_NNS
          to_TO receive_VB epidural_NN analgesia_NN earlier_RBR in_IN the_DT course_NN of_IN
          labor_NN ,_, there_EX was_VBD concern_NN about_IN violating_VBG the_DT fifth_JJ
          requirement_NN of_IN no_DT effect_NN of_IN availability_NN on_IN the_DT effect_NN of_IN
          intervention_NN ._. However_RB ,_, because_IN a_DT randomized_JJ trial_NN had_VBD
          previously_RB shown_VBN that_IN the_DT effect_NN of_IN epidural_NN analgesia_NN on_IN
          the_DT probability_NN of_IN Cesarean_NNP section_NN did_VBD not_RB differ_VB
          whether_IN epidural_NN analgesia_NN was_VBD initiated_VBN early_JJ or_CC late_RB in_IN
          labor_NN ,_, the_DT requirement_NN was_VBD thought_VBN to_TO hold_VB ._. A_DT slightly_RB
          simplified_VBN version_NN of_IN the_DT data_NNS from_IN Baker_NNP and_CC Lindeman_NNP [_NN
          9_CD ]_NN is_VBZ given_VBN in_IN Table_NNP 3_CD ._. In_IN particular_JJ ,_, to_TO simplify_VB the_DT
          calculations_NNS for_IN the_DT hospital_NN designated_VBN as_IN number_NN 11_CD ,_, we_PRP
          regrouped_JJ data_NNS from_IN multiple_JJ time_NN periods_NNS into_IN two_CD time_NN
          periods_NNS ._.
          Using_VBG the_DT aforementioned_JJ method_NN of_IN analysis_NN ,_, with_IN more_JJR
          details_NNS in_IN the_DT notes_NNS for_IN Table_NNP 3_CD ,_, the_DT estimated_VBN increase_NN
          in_IN the_DT probability_NN of_IN Cesarean_NNP section_NN due_JJ to_TO epidural_NN
          analgesia_NN was_VBD -_: 0_CD ._. 005_CD with_IN a_DT 95_CD %_NN confidence_NN interval_NN of_IN
          (_( -_: ._. 047_CD ,_, ._. 037_CD )_) ._. This_DT is_VBZ fairly_RB close_RB to_TO the_DT more_RBR exact_JJ
          calculations_NNS based_VBN on_IN a_DT permutation_NN distribution_NN in_IN [_NN 9_CD ]_NN
          ._. Importantly_NNP ,_, these_DT results_NNS were_VBD similar_JJ to_TO those_DT from_IN a_DT
          meta-analysis_JJ of_IN randomized_JJ trials_NNS adjusted_VBN for_IN switching_NN
          of_IN treatments_NNS that_WDT yielded_VBD an_DT estimate_NN of_IN method_NN
          effectiveness_NN of_IN ._. 02_CD with_IN 95_CD %_NN confidence_NN interval_NN of_IN
          (_( -_: ._. 02_CD ,_, ._. 08_CD )_) [_NN 9_CD ]_NN ._. In_IN contrast_NN ,_, a_DT high_JJ quality_NN
          propensity_NN score_NN analysis_NN of_IN cohort_NN data_NNS gave_VBD a_DT much_RB
          larger_JJR estimate_NN of_IN ._. 10_CD with_IN a_DT 95_CD %_NN confidence_NN interval_NN of_IN
          (_( ._. 07_CD ,_, ._. 13_CD )_) ._. The_DT bias_NN may_MD be_VB due_JJ to_TO the_DT omission_NN of_IN a_DT risk_NN
          factor_NN for_IN intense_JJ pain_NN early_RB in_IN labor_NN [_NN 9_CD ]_NN ._.
        
      
      
        Discussion_NNP
        The_DT paired_VBN availability_NN design_NN has_VBZ promise_NN for_IN
        evaluating_VBG medical_JJ versus_CC surgical_JJ interventions_NNS ._. For_IN such_JJ
        an_DT evaluation_NN ,_, it_PRP would_MD be_VB difficult_JJ to_TO recruit_VB patients_NNS to_TO
        a_DT randomized_JJ trial_NN because_IN few_JJ patients_NNS want_VBP to_TO be_VB
        randomized_JJ to_TO those_DT options_NNS ._. Also_RB ,_, many_JJ physicians_NNS feel_VBP
        uncomfortable_JJ assigning_VBG their_PRP$ patients_NNS to_TO invasive_JJ versus_CC
        non-invasive_JJ interventions_NNS ._. Thus_RB a_DT validated_JJ alternative_JJ
        method_NN of_IN evaluation_NN would_MD be_VB of_IN considerable_JJ value_NN ._. We_PRP
        think_VBP that_IN ,_, in_IN some_DT cases_NNS ,_, the_DT paired_VBN availability_NN design_NN
        would_MD be_VB well_RB suited_VBN for_IN this_DT type_NN of_IN evaluation_NN ._. The_DT key_NN
        to_TO the_DT stable_JJ population_NN requirement_NN is_VBZ having_VBG clear_JJ and_CC
        constant_JJ eligibility_NN criteria_NNS ._. For_IN stable_JJ treatment_NN ,_,
        ancillary_JJ care_NN and_CC the_DT method_NN of_IN evaluation_NN must_MD be_VB the_DT
        same_JJ over_IN time_NN ._. For_IN the_DT stable_NN preference_NN assumption_NN to_TO
        hold_VB ,_, there_EX should_MD be_VB no_DT advertising_NN of_IN the_DT medical_JJ
        intervention_NN ._. For_IN the_DT requirement_NN of_IN no_DT effect_NN of_IN
        availability_NN on_IN the_DT effect_NN of_IN intervention_NN ,_, either_CC the_DT
        surgical_JJ technique_NN should_MD have_VB stabilized_VBN or_CC the_DT design_NN
        should_MD only_RB include_VB hospitals_NNS with_IN no_DT previous_JJ
        surgeries_NNS ._.
        A_DT possible_JJ example_NN would_MD be_VB an_DT analysis_NN of_IN surgical_JJ
        removal_NN of_IN liver_NN metastases_NNS in_IN patients_NNS with_IN colorectal_NN
        cancer_NN ._. Although_IN liver_NN metastatectomy_NN has_VBZ been_VBN associated_VBN
        with_IN favorable_JJ outcomes_NNS ,_, a_DT more_RBR rigorous_JJ evaluation_NN is_VBZ
        needed_VBN ._. An_DT analysis_NN of_IN prospective_JJ cohort_NN data_NNS is_VBZ likely_JJ to_TO
        be_VB biased_VBN because_IN of_IN the_DT difficulty_NN observing_VBG or_CC
        quantifying_VBG important_JJ risk_NN factors_NNS such_JJ as_IN patient_NN
        performance_NN status_NN ,_, tumor_NN doubling_VBG times_NNS ,_, and_CC meticulous_JJ
        staging_NN ._.
        Several_JJ conditions_NNS listed_VBN in_IN Table_NNP 2_CD are_VBP favorable_JJ to_TO a_DT
        paired_VBN availability_NN design_NN ._. The_DT surgical_JJ approach_NN has_VBZ been_VBN
        relatively_RB stable_JJ for_IN years_NNS ._. The_DT use_NN of_IN CT_NNP scans_VBZ and_CC CEA_NNP
        blood_NN testing_NN in_IN follow-up_JJ of_IN patients_NNS after_IN resection_NN of_IN
        the_DT primary_JJ tumor_NN has_VBZ been_VBN popular_JJ for_IN at_IN least_JJS two_CD
        decades_NNS ._. Although_IN systemic_JJ therapy_NN has_VBZ changed_VBN ,_, efficacy_NN of_IN
        chemotherapy_NN for_IN metastatic_JJ disease_NN has_VBZ reached_VBN a_DT plateau_NN ._.
        Metastatectomy_NNP is_VBZ not_RB one_CD of_IN the_DT procedures_NNS heavily_RB
        advertised_VBN by_IN hospitals_NNS or_CC medical_JJ centers_NNS ._. An_DT ideal_JJ
        circumstance_NN would_MD be_VB to_TO apply_VB the_DT paired_VBN availability_NN
        design_NN to_TO hospitals_NNS before_IN and_CC after_IN the_DT arrival_NN of_IN a_DT
        surgical_JJ oncologist_NN who_WP brings_VBZ the_DT procedure_NN into_IN common_JJ
        practice_NN for_IN the_DT first_JJ time_NN at_IN that_DT hospital_NN ._.
        A_DT well-designed_JJ randomized_JJ study_NN of_IN liver_NN metastatectomy_NN
        would_MD still_RB give_VB a_DT more_RBR statistically_RB valid_JJ assessment_NN of_IN
        the_DT procedure_NN than_IN the_DT paired_VBN availability_NN design_NN ._. However_RB ,_,
        such_JJ a_DT randomized_JJ study_NN has_VBZ never_RB been_VBN done_VBN ,_, despite_IN the_DT
        use_NN of_IN metastatectomy_NN for_IN many_JJ years_NNS ._. A_DT paired_VBN availability_NN
        design_NN would_MD likely_RB be_VB subject_JJ to_TO fewer_JJR biases_NNS than_IN a_DT
        cohort_NN study_NN comparing_VBG outcomes_NNS of_IN patients_NNS who_WP did_VBD versus_CC
        those_DT who_WP did_VBD not_RB undergo_VB the_DT surgical_JJ procedure_NN ._.
        To_TO decide_VB if_IN a_DT method_NN for_IN analyzing_VBG observational_NN data_NNS
        is_VBZ generally_RB reliable_JJ ,_, one_PRP should_MD have_VB experience_VB comparing_VBG
        the_DT results_NNS to_TO those_DT obtained_VBN from_IN a_DT randomized_JJ trial_NN ._. In_IN
        the_DT only_JJ application_NN of_IN the_DT paired_VBN availability_NN design_NN to_TO
        date_NN ._. Baker_NNP and_CC Lindeman_NNP obtained_VBD similar_JJ results_NNS from_IN the_DT
        paired_VBN availability_NN design_NN as_IN from_IN a_DT meta-analysis_JJ of_IN
        randomized_JJ trials_NNS ._. These_DT results_NNS differed_VBD substantially_RB
        from_IN a_DT multivariate_NN adjustment_NN for_IN concurrent_JJ controls_NNS ,_,
        which_WDT likely_RB omitted_VBD an_DT important_JJ risk_NN factor_NN 2_CD ._. Hopefully_NNP
        this_DT article_NN will_MD spur_VB new_JJ studies_NNS using_VBG the_DT paired_VBN
        availability_NN design_NN ,_, including_VBG some_DT comparing_VBG the_DT results_NNS
        to_TO those_DT from_IN randomized_JJ trials_NNS ._.
      
      
        Conclusion_NNP
        We_PRP wish_VBP to_TO emphasize_VB that_IN the_DT randomized_JJ trial_NN
        represents_VBZ the_DT strongest_JJS form_NN of_IN evaluation_NN and_CC should_MD be_VB
        implemented_VBN if_IN possible_JJ ._. However_RB we_PRP recognize_VBP that_IN there_EX
        are_VBP situations_NNS where_WRB the_DT randomized_JJ trial_NN is_VBZ difficult_JJ to_TO
        implement_VB ,_, such_JJ as_IN comparing_VBG medical_JJ versus_CC surgical_JJ
        interventions_NNS ._. If_IN the_DT requirements_NNS for_IN the_DT paired_VBN
        availability_NN design_NN are_VBP met_VBN ,_, we_PRP recommend_VBP it_PRP as_IN an_DT
        alternative_NN with_IN advantages_NNS over_IN the_DT usual_JJ analyses_NNS from_IN
        observational_NN studies_NNS ._.
      
      
        Competing_VBG Interests_NNP
        None_NNP Declared_NNP
      
    
  
